HIGHBuilt-in & outside partyProduct / Revenue mix
Optune Gio (glioblastoma)
“10-K Item 1A: 'almost all of our revenues will derive from sales and royalties from sales of Optune Gio for the treatment of newly diagnosed and recurrent GBM.'”
NVCR · Concentration risk · 10-K extracted
NovoCure (NVCR) concentration risks
Updated
The most significant concentration NovoCure discloses is Optune Gio (glioblastoma), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: NovoCure’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH1
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
United States, Germany, France and Japan
“10-K Item 1: 'We market our Products in multiple countries around the globe with the majority of our revenues coming from the use of Optune Gio in the U.S., Germany, France and Japan.'”
MEDIUMOutside partyCounterparty
Zai Lab (Greater China license)
“10-K Item 1A: 'we have exclusively licensed rights to commercialize our Products in the field of oncology in Greater China to Zai pursuant to an agreement that also establishes a development partnership'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06NovoCure's concentration profile layers a product dependency with geographic and partner-based exposures. Almost all of the company's revenue derives from sales and royalties of Optune Gio for glioblastoma, a high, mixed-character exposure reflecting both the structural reality of a single-product commercial base and the practical risk of relying on one indication for essentially all revenue. Geographically, the majority of revenue comes from the U.S., Germany, France and Japan, a moderate, structural concentration spread across four developed markets rather than one. Commercialization in Greater China runs through an exclusive license to Zai Lab under a development partnership, a moderate dependency on a single regional partner. The product concentration is the exposure most capable of moving the verdict, since it sits upstream of both the geographic and partner exposures — any change in Optune Gio's competitive position or reimbursement would flow through all four core markets and the Zai Lab partnership simultaneously. The four-market geographic spread offers some diversification relative to a single-country dependency, while the Zai Lab arrangement is a narrower, partner-specific risk limited to the Greater China opportunity.
For the engine’s reasoning on NVCR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| NVCR● | NovoCure Limited | 1 | 2 | 0 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.